Information  X 
Enter a valid email address
  Print          More announcements

Thursday 28 September, 2000

Evotec BioSystems

Offer for OAI: Offer Update

Evotec BioSystems AG
28 September 2000


Not for release, publication or distribution in or into the
United States, Australia, Canada or Japan.


  Recommended Offer by Lehman Brothers on behalf of EVOTEC
BioSystems AG  ('EVOTEC') for Oxford Asymmetry International
    plc ('OAI') declared unconditional as to acceptances
                              
                              
EVOTEC announces that at 3.00 p.m. on 28 September 2000,
valid acceptances of the Offer had been received in respect
of 34,121,576 OAI Shares, representing approximately 80.9
per cent. of OAI's existing issued ordinary share capital.
These acceptances include acceptances pursuant to
irrevocable undertakings to accept the Offer from the
Directors of OAI and certain other OAI Shareholders in
respect of 14,155,367 OAI Shares, representing approximately
33.6 per cent. of OAI's existing issued ordinary share
capital, which were given immediately prior to the
announcement of the Offer by EVOTEC on 31 July 2000.

The Offer has now been declared unconditional as to
acceptances and will remain open for acceptance until
further notice.

A further announcement will be made in due course regarding
fulfilment or waiver of the remaining conditions of the
Offer.

Save as disclosed above, neither EVOTEC nor any party deemed
to be acting in concert with EVOTEC has acquired or agreed
to acquire any OAI Shares (or rights over such shares) since
18 July 2000, the last day prior to the commencement of the
Offer Period nor did any such person hold any OAI Shares (or
rights over such shares) on 18 July 2000.


Enquiries

Lehman Brothers                    Tel:  +44 (0)20 7601 0011
Warwick Ball

Definitions used in the offer document dated 12 August 2000
have the same meanings when used in this announcement,
unless the context requires otherwise.

Lehman Brothers, which is regulated in the UK by The
Securities and Futures Authority Limited, is acting for
EVOTEC BioSystems AG in connection with the Offer and no-one
else and will not be responsible to anyone other than EVOTEC
BioSystems AG for providing the protections afforded to
customers of Lehman Brothers, nor for providing advice in
relation to the Offer.

The Offer is not being made, directly or indirectly, in or
into Australia, Canada or Japan, and it may not be accepted
in or from Australia, Canada or Japan.  In addition, the
Offer is not being made, directly or indirectly in or into
the United States, and, subject to certain exceptions, the
Offer may not be accepted from the United States.

The New EVOTEC Shares proposed to be issued in connection
with the Offer will not be registered under the U.S.
Securities Act of 1933, as amended.  This announcement does
not constitute an offer of securities for sale in the United
States.  No public offering of securities will be made in
the United States in connection with the Offer.



                                                                                
                

a d v e r t i s e m e n t